Trial record 1 of 2 for:    Hepatocellular Carcinoma GenSpera
Previous Study | Return to List | Next Study

Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma (G-202-003)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GenSpera, Inc.
ClinicalTrials.gov Identifier:
NCT01777594
First received: January 18, 2013
Last updated: December 8, 2015
Last verified: December 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)